Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.42 |
| ▸ | PPARD | Q03181 | 8/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | XDH | P47989 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586586 | 0.85 | XDH (0.43) | TAS2R14XDH | |
| SCHEMBL3583718 | 0.84 | XDH (0.42) | TAS2R14XDH | |
| SCHEMBL3593046 | 0.83 | XDH (0.42) | XDH | |
| SCHEMBL3583722 | 0.82 | XDH (0.41) | XDH | |
| SCHEMBL3586916 | 0.82 | XDH (0.54) | XDH | |
| SCHEMBL3588186 | 0.81 | XDH (0.43) | MRGPRX4XDH | |
| SCHEMBL3579351 | 0.81 | XDH (0.52) | XDH | |
| SCHEMBL3583133 | 0.81 | XDH (0.48) | XDH | |
| SCHEMBL3588914 | 0.81 | AR (0.41) | TAS2R14PPARAXDH | |
| SCHEMBL3589529 | 0.80 | XDH (0.51) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128136-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | XDH, NUDT1, PNPO | TAS2R14 3466/4885MRGPRX4 3567/4885PPARD 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.